|JDRF’s research mission is to discover, |
develop and deliver advances that cure, better treat and prevent type 1 diabetes (T1D).
Over the past 23 years the JDRF Seattle Guild's Annual Dream Gala is proud to have contributed over $56 million to diabetes research. Bringing us closer to a cure.
View the JDRF Research Top 10 Advances of FY2012
JDRF 'Cure' Research
Targeted Immune Rebalancing Therapy Starts Clinical Study
A JDRF-supported study launched at the University of California at San Francisco is enrolling patients with recent onset T1D to test a therapy for rebalancing their immune system. A patient’s “T-regs” (cells that regulate the immune system) will be grown in the lab then re-infused to the patient. The hope is that these added T-regs will halt the destructive “killer” T-effector cells that attack beta cells. This milestone represents the first human test of such a T1D therapy.
JDRF 'Treat' Research
FDA Issues Draft AP System Guidance as a Result of JDRF-Led Effort
JDRF-led grassroots advocacy including support from professional clinical associations helped drive FDA to produce draft guidance for development of artificial pancreas systems. While JDRF provided FDA suggestions to improve the draft guidance, the expectations for clinical studies and approval of such systems are reasonable. JDRF is working closely with the FDA as the draft guidance is finalized. This guidance will speed JDRF’s APP clinical studies, especially outpatient studies, by informing researchers and companies of FDA’s recommendations. (Learn more at jdrf.org/app/plan)
For more information, visit the JDRF web site at www.jdrf.org or call 800-533-CURE.
JDRF 'Prevent' Research
Focused a Novel Vaccine Technology on T1D Prevention
Targeted T1D vaccines are ones focused on the specific beta cell components to which the immune system mistakenly reacts. A vaccine focused on these beta cell components could stop the autoimmune process before a person becomes insulin dependent. JDRF is supporting this unique nanoparticle-based vaccine technology by partnering with Selecta (a Massachusetts based company) to ensure they focus their efforts on T1D, something not previously a priority for them. Vaccine research is one of the most promising approaches to prevent or halt the beta cell-specific autoimmunity in T1D. (Learn more at jdrf.org/prevention/strategy)
Diabetes is the name given to disorders in which the body has trouble regulating its blood glucose, or blood sugar, levels. There are two major types of diabetes: type 1 and type 2.
Type 1 diabetes (T1D) is an autoimmune disease in which a person’s pancreas stops producing insulin, a hormone that enables people to get energy from food. T1D usually strikes in childhood, adolescence,
or young adulthood, and lasts a lifetime. Just to survive, people with T1D must take multiple injections of insulin daily or continually infuse insulin through a pump. Taking insulin does not cure any type of diabetes, nor does it prevent the possibility of the disease’s devastating effects: kidney failure, blindness, nerve damage, amputation, heart attack, stroke,
and pregnancy complications.
The Scope of Diabetes
- Nearly 26 million Americans have diabetes (8.3 percent of the population)
- Diagnosed: 18.8 million
- Undiagnosed: 7 million
- Diabetes currently affects 366 million people worldwide and is expected to affect 552 million by 2030.
- In the U.S., a new case of diabetes is diagnosed every 30 seconds; more than 1.9 million people are diagnosed each year.
Because it changes lives;
Because you never outgrow it;
Because it is there every minute of every day;
We need a cure.
|The Sixth Annual
JDRF Seattle Guild
Invitational Golf Tournament
Monday, September 9, 2013
at Glendale Country Club
Please join us for a fantastic day of golf, including on-course games, contests, auction and dinner. All proceeds will benefit JDRF-funded research efforts to treat, prevent and ultimately cure type 1 diabetes. For more information, contact the
JDRF Seattle Guild office at
(206)343-0873 or email@example.com
THE 2013 MXD CHAMPIONSHIPS
An All-Mixed Doubles Tennis Event
July 25-28, 2013
Nearly 250 tennis players participate in the all-mixed doubles tournament, and over 300 guests attend the player party and auction. Participants are energetic, family-oriented, professional and enjoy active lifestyles.
For more information, visit: